drugset
drugset / Trial / NCT02096679

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in Volunteers

NCT02096679 ↗

Phase 1 Completed 8 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelBasic science

Summary

Study to evaluate the pharmacokinetic and Mass Balance of single dose \[14C\] AZD9291 in healthy male volunteers

Timeline

Start
2014-05
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Osimertinib Small molecule 20 mg Oral

Indications

No indication recorded.